← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
BENTSUR RON
Chief Executive Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001251213
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 4
- Average purchase
- $99.5K
- Median purchase
- $63.5K
- Gross purchase value
- $397.9K
Companies: Nuvectis Pharma, Inc.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-01 | Nuvectis Pharma, Inc. | NVCT | Chief Executive Officer | $250.0K | Open filing |
| 2025-11-06 | Nuvectis Pharma, Inc. | NVCT | Chief Executive Officer | $28.6K | Open filing |
| 2024-12-26 | Nuvectis Pharma, Inc. | NVCT | Chief Executive Officer | $20.9K | Open filing |
| 2024-11-18 | Nuvectis Pharma, Inc. | NVCT | Chief Executive Officer | $98.4K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/3
- Large purchase ≥ $100k
- 1/4
- Cluster buying · 15D
- 3/4
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.